The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
FC, IF
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is 20 µl per million cells or 20 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application References:
1. Bühring, H.J., et al., 1995. Blood 86:1916.
Human breast cancer cell line (MCF-7) stained with 24D2 FITC
Description:
The 24D2 recognizes human CD340 also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. CD340 is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain with an approximate molecular weight of 185 kD. CD340 Contains three furin repeats and two cheY homologous receiver domains in the extracellular region. The HER2/erbB2 protein is expressed on many tumor cells including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow MSC. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression; this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Over-expression of ERBB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphoryation on multiple residues (Y 1023, Y1139, Y1196, Y1221, Y1222, Y1248). The 24D2 antibody has been shown to be useful for flow cytometry.
Member of the epidermal growth factor receptor family of cell membrane tyrosine kinases. Single transmembrane pass protein with an approximate molecular weight of 185 kD. Contains three furin repeats and two cheY homologous receiver domains in the extrace
Distribution:
Expressed on many tumor cells including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow MSC
Function:
The erbB2/HER2 protein contains no ligand binding domain and interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. Involved in embryonic development and cancer p
Modification:
Extensively modified by tyrosine phosphoryation on multiple residues (Y 1023, Y1139, Y1196, Y1221, Y1222, Y1248)
Interaction:
CD340 (HER2/erbB2) interacts with a large number of proteins including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others
Antigen References:
1. Akiyama, T., et al. 1986. Science 232:1644. 2. Bargmann, C.I., et al. 1986. Nature 319:226. 3. Pegram, M.D., et al. 1997. Oncogene 15:537. 4. Slamon, D.J., et al. 1989. Science 244:707.
